Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073

Ferlay, 2010, Estimates of cancer incidence and mortality in Europe in 2008, Eur J Cancer, 46, 765, 10.1016/j.ejca.2009.12.014

Schulman, 2007, Economic burden of metastatic bone disease in the U.S., Cancer, 109, 2334, 10.1002/cncr.22678

Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458

Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141

Roudier, 2008, Histopathological assessment of prostate cancer bone osteoblastic metastases, J Urol, 180, 1154, 10.1016/j.juro.2008.04.140

Brown, 2005, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors, J Natl Cancer Inst, 97, 59, 10.1093/jnci/dji002

Demers, 2003, Bone markers in the management of patients with skeletal metastases, Cancer, 97, 874, 10.1002/cncr.11127

Percival, 1987, Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption, Eur J Surg Oncol, 13, 41

Boyle, 2003, Osteoclast differentiation and activation, Nature, 423, 337, 10.1038/nature01658

Fizazi, 2003, Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts, Clin Cancer Res, 9, 2587

Zhang, 2003, Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone, Cancer Res, 63, 7883

Fizazi, 2009, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 27, 1564, 10.1200/JCO.2008.19.2146

2009

Hung, 2003, Some fundamental issues with non-inferiority testing in active controlled trials, Stat Med, 22, 213, 10.1002/sim.1315

Anderson, 1982, Cox's regression model for counting processes: a large sample study, Ann Statistics, 10, 1100

Westfall, 1999

Lee, 2011, Treatment and prevention of bone complications from prostate cancer, Bone, 48, 88, 10.1016/j.bone.2010.05.038

Small, 2003, Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer, J Clin Oncol, 21, 4277, 10.1200/JCO.2003.05.147

Olson, 2007, Significance and impact of bisphosphonate-induced acute phase responses, J Oncol Pharm Pract, 13, 223, 10.1177/1078155207080806

Ellis, 2008, Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer, J Clin Oncol, 26, 4875, 10.1200/JCO.2008.16.3832

Lipton, 2007, Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases, J Clin Oncol, 25, 4431, 10.1200/JCO.2007.11.8604

Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003

Walter, 2008, Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate, Eur Urol, 54, 1066, 10.1016/j.eururo.2008.06.070

Dearnaley, 2009, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, Lancet Oncol, 10, 872, 10.1016/S1470-2045(09)70201-3

Saad, 2008, New research findings on zoledronic acid: survival, pain, and anti-tumour effects, Cancer Treat Rev, 34, 183, 10.1016/j.ctrv.2007.10.002

Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

Fizazi, 2010, Role of targeted therapy in the treatment of advanced prostate cancer, BJU Int, 105, 748, 10.1111/j.1464-410X.2010.09236.x

James, 2009, Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial, Eur Urol, 55, 1112, 10.1016/j.eururo.2008.11.002

Fizazi, 2009, Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer, J Clin Oncol, 27, 2429, 10.1200/JCO.2008.18.9811

Nilsson, 2007, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study, Lancet Oncol, 8, 587, 10.1016/S1470-2045(07)70147-X

Henry D, Costa L, Goldwasser F, et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (in press).

Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101